Profound arranges $40-million financing

Executive Summary

• Profound Medical Corp. announced the pricing of an aggregate financing of up to $40 million, consisting of a $36 million registered direct offering and a subsequent $4 million private placement in Canada.
• The registered direct offering involves the sale of 5,142,857 common shares at $7 per share, with no warrant coverage, expected to close around December 22, 2025.
• The company intends to use the net proceeds for sales and marketing expansion, working capital, research and development, strategic transactions, and general corporate purposes.

Key Details

• Total Financing Amount: Up to $40 million in aggregate gross proceeds.
• Registered Direct Offering:
  • Structure: Straightforward equity investment with no warrant coverage.
  • Shares: 5,142,857 common shares.
  • Price: $7.00 per share.
  • Gross Proceeds: Approximately $36 million (before deducting placement agent's fees and offering expenses).
  • Closing Date: Expected on or about Monday, Dec. 22, 2025, subject to customary closing conditions.
  • Placement Agent: Konik Capital Partners LLC, a division of T.R. Winston and Company LLC, acting as exclusive placement agent.
  • Regulatory Basis: Made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291516), declared effective by the SEC on Dec. 4, 2025.
• Private Placement (Canada):
  • Structure: Private placement to certain Canadian purchasers.
  • Shares: Up to 571,428 common shares.
  • Price: $7.00 per share.
  • Gross Proceeds: Up to $4 million.
  • Hold Period: Common shares subject to a hold period of four months plus one day from the closing date.
  • Closing Date: Expected on or prior to Dec. 30, 2025.
  • Conditions: Subject to necessary approvals, including conditional approval from the Toronto Stock Exchange.
  • Restrictions: No securities sold to U.S. purchasers.
• Use of Proceeds: Expansion of sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes.

Notable Quotes

• No direct quotes from the CEO or President were included in the provided text.